Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 16629859 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE | March 2021 | May 2024 | Allow | 52 | 1 | 0 | No | No |
| 17256095 | MINI COMBINED ADJUVANTS CARRIER-FREE NANOPARTICLES AND PREPARATION METHOD AND APPLICATION THEREOF | December 2020 | July 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17132440 | METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE | December 2020 | April 2022 | Abandon | 16 | 2 | 0 | No | No |
| 17251698 | PLANT PRODUCED PORCINE CIRCOVIRUS PSEUDOVIRION | December 2020 | July 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17116227 | COVID-19 PEPTIDE SPECIFIC T-CELLS AND METHODS OF TREATING AND PREVENTING COVID-19 | December 2020 | October 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 17108608 | NEUTRALIZING ANTI-INFLUENZA BINDING MOLECULES AND USES THEREOF | December 2020 | July 2022 | Allow | 20 | 2 | 0 | No | No |
| 17104457 | TRIPLE VACCINE AGAINST AVIBACTERIUM PARAGALLINARUM AND AVIAN ENCEPHALOMYELITIS VIRUS AND FOWL POX VIRUS | November 2020 | September 2022 | Allow | 22 | 2 | 0 | No | No |
| 16950297 | Mosaic Chimeric Viral Vaccine Particle | November 2020 | February 2022 | Allow | 15 | 1 | 0 | No | No |
| 17098449 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE | November 2020 | June 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17054333 | NUCLEIC ACID FOR TREATING CRUSTACEAN ALLERGY | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17067144 | RIFT VALLEY FEVER VACCINE | October 2020 | March 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17065535 | IMMUNOGENIC COMPOSITION FOR PORCINE EPIDEMIC DIARRHEA VIRUS | October 2020 | April 2022 | Abandon | 18 | 1 | 0 | No | No |
| 17046210 | RECOMBINANT VIRUS CAPABLE OF STABLY EXPRESSING TARGET PROTEINS | October 2020 | September 2023 | Allow | 35 | 1 | 1 | No | No |
| 17045322 | Live-Attenuated Yellow Fever Virus Strain Adapted to Grow on Vero Cells and Vaccine Composition Comprising the Same | October 2020 | June 2022 | Allow | 20 | 2 | 0 | No | No |
| 17043979 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES | September 2020 | October 2022 | Allow | 25 | 4 | 0 | No | No |
| 17041578 | METHOD FOR LARGE-SCALE PRODUCTION OF LENTIVIRUS BY USING GMP-LEVEL SERUM-FREE SUSPENSION CELLS | September 2020 | September 2023 | Allow | 36 | 0 | 0 | No | No |
| 17042125 | METHOD FOR LARGE-SCALE PREPARATION OF PURIFIED PREPARATION OF RECOMBINANT LENTIVIRAL VECTOR AT GMP GRADE | September 2020 | February 2024 | Allow | 41 | 1 | 0 | No | No |
| 17041870 | IRRADIATION-INACTIVATED POLIOVIRUS, COMPOSITIONS INCLUDING THE SAME, AND METHODS OF PREPARATION | September 2020 | March 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17030793 | PLANT VIRUS PARTICLES FOR DELIVERY OF ANTIMITOTIC AGENTS | September 2020 | October 2021 | Allow | 13 | 1 | 0 | No | No |
| 17031082 | A RECOMBINANT HOST CELL WITH HETEROLOGOUS NUCLEIC ACIDS ENCODING SHREK PROTEINS | September 2020 | July 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16982682 | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION | September 2020 | July 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 17021261 | PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM | September 2020 | January 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 16980785 | METHOD OF PRODUCING AN IMMUNOGENIC COMPOSITION | September 2020 | December 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16980723 | NEW EHV INSERTION SITE UL43 | September 2020 | April 2022 | Allow | 19 | 2 | 0 | Yes | No |
| 17017342 | Recombinant Herpesvirus of Turkey Vectors Expressing Antigens of Avian Pathogens and Uses Thereof | September 2020 | April 2022 | Allow | 19 | 1 | 0 | No | No |
| 16979780 | VACCINE COMPOSITIONS COMPRISING A WATER-IN-OIL EMULSION, IMMUNOGEN-LOADED HYDROGEL PARTICLES, AND CATIONIC POLYMER | September 2020 | February 2022 | Allow | 17 | 1 | 0 | No | No |
| 16992760 | METHOD FOR DETECTION AND MITIGATION OF COMPOUND PRODUCING MICROBIOTA IN AN AQUACULTURE SYSTEM | August 2020 | June 2024 | Abandon | 46 | 3 | 0 | No | No |
| 16988835 | Antibodies Against F Glycoprotein of Hendra and Nipah Viruses | August 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16944649 | SEVERE ACUTE RESPIRATORY SYNDROME (SARS) - ASSOCIATED CORONAVIRUS DIAGNOSTICS | July 2020 | January 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 16941481 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | July 2020 | June 2023 | Allow | 34 | 1 | 1 | No | No |
| 16965589 | RSV RNA VACCINES | July 2020 | October 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16964632 | RECOMBINANT PROTEIN FOR REMOVING BOAR TAINT AND VACCINE COMPOSITION COMPRISING THE SAME | July 2020 | May 2024 | Abandon | 46 | 1 | 0 | No | No |
| 16933157 | VETERINARY IMMUNOCONTRACEPTIVE VACCINE AND ADJUVANT | July 2020 | October 2022 | Abandon | 26 | 2 | 0 | No | No |
| 16962886 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | July 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16960222 | RECOMBINANT H7N9 SUBTYPE AVIAN INFLUENZA VIRUS, INACTIVATED MARKED VACCINE AND PREPARATION METHOD THEREOF | July 2020 | March 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16957511 | ONCOLYTIC VIRUS IMPROVED IN SAFETY AND ANTICANCER EFFECT | June 2020 | July 2023 | Allow | 37 | 1 | 1 | No | No |
| 16909311 | VIRAL VACCINES FOR IN VIVO EXPRESSION OF A NUCLEIC ACID ENCODING AN IMMUNOGENIC PEPTIDE AND METHODS OF USING THE SAME | June 2020 | August 2022 | Allow | 25 | 4 | 0 | Yes | No |
| 16906134 | COMPOSITION OF SUBUNIT DENGUE VACCINE | June 2020 | July 2023 | Allow | 37 | 2 | 0 | Yes | Yes |
| 16906450 | NEW ROUTE AND ENGINEERING PROTOCOLS FOR ALZHEIMERS DISEASE PREVENTION, TREATMENT AND NEURONAL REBUILDING | June 2020 | May 2024 | Abandon | 47 | 2 | 1 | Yes | No |
| 16955015 | INTRADERMAL COMBINATION VACCINE AGAINST MYCOPLASMA AND PORCINE CIRCOVIRUS | June 2020 | April 2023 | Allow | 34 | 3 | 0 | Yes | No |
| 16900798 | SEROLOGICAL ASSAYS FOR SARS-COV-2 | June 2020 | May 2021 | Allow | 11 | 1 | 0 | No | No |
| 16771800 | HORNFLY VACCINE METHODS | June 2020 | May 2023 | Allow | 36 | 1 | 1 | No | No |
| 16771648 | DRY ADJUVANTED IMMUNE STIMULATING COMPOSITIONS AND USE THEREOF FOR MUCOSAL ADMINISTRATION | June 2020 | October 2023 | Allow | 40 | 4 | 0 | No | No |
| 16896985 | BOVINE HERPESVIRUS DETECTION AND TREATMENT | June 2020 | October 2021 | Allow | 17 | 1 | 0 | No | No |
| 16771022 | IMPROVED DILUENT FOR CELL-ASSOCIATED ALPHAHERPESVIRUS VACCINE | June 2020 | December 2021 | Allow | 18 | 1 | 0 | No | No |
| 16770639 | RECOMBINANT SWINEPOX VIRUS ENCODING A PCV3 ANTIGEN | June 2020 | December 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16770636 | RECOMBINANT SWINEPOX VIRUS AND VACCINES | June 2020 | December 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16769837 | FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS | June 2020 | August 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16769820 | LIQUID VACCINES OF LIVE ENVELOPED VIRUSES | June 2020 | February 2022 | Allow | 20 | 2 | 0 | Yes | No |
| 16888752 | Herb and Root Infused Carrier Oil | May 2020 | March 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16886387 | NON-NATURALLY OCCURING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF USING | May 2020 | June 2021 | Allow | 12 | 1 | 0 | Yes | No |
| 16879471 | METHODS OF MANUFACTURING AN IMMUNOGENIC COMPOSITION COMPRISING A RECOMBINANT PROTEIN | May 2020 | April 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16879668 | Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines | May 2020 | May 2022 | Allow | 24 | 2 | 0 | No | No |
| 16765770 | H5 AVIAN INFLUENZA VACCINE STRAIN WHICH DIFFERENTIATES INFECTED FROM VACCINATED ANIMALS, PREPARATION METHOD THEREFOR, AND APPLICATION | May 2020 | October 2022 | Allow | 29 | 1 | 0 | No | No |
| 16877319 | RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 1 (HPIV1) EXPRESSING A CHIMERIC RSV/HPIV1 F PROTEIN AND USES THEREOF | May 2020 | October 2022 | Allow | 29 | 1 | 1 | No | No |
| 16869901 | Computational Algorithm for Universal Vaccine Selection | May 2020 | March 2022 | Allow | 22 | 2 | 0 | No | No |
| 16761368 | Zika Vaccines and Immunogenic Compositions, and Methods of Using the Same | May 2020 | September 2022 | Allow | 29 | 2 | 0 | No | No |
| 16761049 | Method for Acclimating and Suspending Vero and Second Order Production Process for Virus | May 2020 | December 2022 | Allow | 32 | 1 | 0 | No | No |
| 16760160 | MULTIVALENT FELINE VACCINE | April 2020 | June 2021 | Allow | 14 | 1 | 0 | No | No |
| 16759945 | FELINE CALICIVIRUS VACCINE | April 2020 | September 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16860308 | PCV/MYCOPLASMA HYOPNEUMONIAE VACCINE | April 2020 | August 2021 | Allow | 15 | 1 | 0 | No | No |
| 16859093 | MYCOPLASMA HYOPNEUMONIAE VACCINE | April 2020 | August 2021 | Allow | 15 | 1 | 0 | No | No |
| 16873472 | Cure to new viruses and other diseases that do not have current cure | April 2020 | May 2024 | Abandon | 49 | 3 | 0 | Yes | Yes |
| 16756490 | RECOMBINANT EXPRESSION OF PCV2B ORF2 PROTEIN IN INSECT CELLS | April 2020 | October 2021 | Allow | 18 | 1 | 0 | No | No |
| 16841485 | Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof | April 2020 | March 2023 | Allow | 35 | 4 | 0 | Yes | No |
| 16753303 | MOSAIC HIV-1 ENVELOPES TO INDUCE ADCC RESPONSES | April 2020 | August 2022 | Allow | 28 | 0 | 1 | No | No |
| 16830412 | IMMUNOGENIC COMPOSITIONS AND VACCINES COMPRISING AFRICAN SWINE FEVER VIRUS PEPTIDES AND PROTEINS AND USES THEREOF | March 2020 | February 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16649456 | PARAMYXOVIRIDAE EXPRESSION SYSTEM | March 2020 | March 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16822830 | EFFECTIVE VACCINATION AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS PRIOR TO WEANING | March 2020 | February 2022 | Allow | 23 | 2 | 0 | No | No |
| 16809038 | NORTH AMERICAN PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS AND USES THEREOF | March 2020 | February 2022 | Allow | 23 | 1 | 1 | No | No |
| 16641012 | METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3 | February 2020 | June 2022 | Allow | 28 | 1 | 1 | No | No |
| 16641064 | BUNYAVIRALES VACCINE | February 2020 | August 2022 | Allow | 30 | 1 | 1 | No | No |
| 16634756 | A VACCINE COMPRISING A PCV2 ORF2 PROTEIN OF GENOTYPE 2B | January 2020 | April 2021 | Allow | 14 | 1 | 0 | No | No |
| 16750437 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE | January 2020 | August 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16749241 | PCV2 ORF2 CARRIER PLATFORM | January 2020 | June 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16623684 | ANTI-ANGIOGENIN PEPTIDES, COMPOSITIONS, AND METHODS OF USE | December 2019 | August 2023 | Allow | 44 | 0 | 0 | No | No |
| 16712605 | METHODS OF IMPROVING EFFICACY OF ALLERGY VACCINES | December 2019 | December 2021 | Abandon | 24 | 1 | 0 | No | No |
| 16711873 | UNIVERSAL INFLUENZA VACCINE | December 2019 | April 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16622023 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | December 2019 | January 2023 | Allow | 38 | 1 | 1 | No | No |
| 16706371 | METHOD FOR THE DETECTION AND CLASSIFICATION OF PRRSV-INFECTIONS IN SWINE HERDS AND DIAGNOSTIC ANTIGEN COMPOSITIONS FOR SUCH METHODS | December 2019 | December 2020 | Abandon | 12 | 1 | 0 | No | No |
| 16702287 | ATTENUATED PORCINE SAPELOVIRUS STRAIN AND IMMUNOGENIC COMPOSITIONS THEREFROM | December 2019 | June 2021 | Allow | 18 | 1 | 1 | No | No |
| 16697418 | Method of Producing High-Strength Composite Sheet Composed of Fiber-Reinforced Grown Biological Matrix | November 2019 | June 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16616212 | NOVEL MURINE PARVOVIRUS AND USES THEREOF | November 2019 | January 2022 | Allow | 26 | 0 | 1 | No | No |
| 16690733 | ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES | November 2019 | July 2023 | Allow | 43 | 1 | 2 | No | No |
| 16688561 | PLANT VIRUS PARTICLES FOR DELIVERY OF ANTIMITOTIC AGENTS | November 2019 | August 2020 | Allow | 9 | 1 | 0 | No | No |
| 16607845 | SINGLE-DOSE VZV VACCINATION METHOD | October 2019 | November 2022 | Abandon | 37 | 3 | 0 | No | No |
| 16606502 | RECOMBINANT GALLID HERPESVIRUS 3 VACCINES ENCODING HETEROLOGOUS AVIAN PATHOGEN ANTIGENS | October 2019 | February 2022 | Allow | 28 | 2 | 0 | No | Yes |
| 16600067 | PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | October 2019 | November 2020 | Allow | 13 | 2 | 0 | Yes | No |
| 16598110 | VACCINE AGAINST PORCINE PARVOVIRUS | October 2019 | June 2020 | Allow | 8 | 1 | 0 | No | No |
| 16589247 | Live-Attenuated Vaccine Having Mutations in Viral Polymerase for the Treatment and Prevention of Canine Influenza Virus | October 2019 | March 2021 | Allow | 17 | 3 | 0 | No | No |
| 16498824 | NOROVIRUS ANTIBODY | September 2019 | October 2022 | Allow | 36 | 1 | 0 | No | No |
| 16580058 | DEVELOPMENT OF A NOVEL LIVE ATTENUATED AFRICAN SWINE FEVER VACCINE BASED IN THE DELETION OF GENE I177L | September 2019 | January 2021 | Allow | 16 | 1 | 0 | No | No |
| 16496244 | NOROVIRUS FUSION PROTEINS AND VLPS COMPRISING NOROVIRUS FUSION PROTEINS | September 2019 | October 2022 | Allow | 37 | 3 | 1 | No | No |
| 16575121 | INTRANASAL VECTOR VACCINE AGAINST PORCINE EPIDEMIC DIARRHEA | September 2019 | October 2020 | Allow | 13 | 1 | 0 | Yes | No |
| 16571616 | FUSION PROTEINS CONTAINING LUCIFERASE AND A POLYPEPTIDE OF INTEREST | September 2019 | April 2020 | Allow | 7 | 1 | 0 | No | No |
| 16493986 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | September 2019 | September 2022 | Allow | 36 | 2 | 0 | No | No |
| 16494211 | Vaccine | September 2019 | February 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16566330 | EXPRESSION OF PEDV SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME | September 2019 | September 2022 | Allow | 36 | 1 | 0 | No | No |
| 16560040 | NEUTRALIZING ANTI-INFLUENZA BINDING MOLECULES AND USES THEREOF | September 2019 | September 2020 | Allow | 13 | 1 | 0 | No | No |
| 16556791 | COMPOSITION FOR DETECTING POTATO VIRUS Y INCLUDING M13KO7 BACTERIOPHAGE AND KIT INCLUDING THE SAME | August 2019 | May 2021 | Allow | 21 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FOLEY, SHANON A.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FOLEY, SHANON A works in Art Unit 1648 and has examined 682 patent applications in our dataset. With an allowance rate of 67.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner FOLEY, SHANON A's allowance rate of 67.3% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by FOLEY, SHANON A receive 1.65 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by FOLEY, SHANON A is 26 months. This places the examiner in the 73% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +22.6% benefit to allowance rate for applications examined by FOLEY, SHANON A. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.1% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 59.1% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 78.3% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 80.8% are granted (fully or in part). This grant rate is in the 84% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.8% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.